Molecular Horizons Seminar - Dr Sam Brennan

Since mid-2019, GenieUs Genomics has been developing bioinformatic pipelines capable of uncovering molecular causes and drivers of ALS pathology. We recognize that there is an incredible diversity of potential disease driving mechanisms in ALS, particularly in the sporadic population, and have developed our pipeline to perform multi-omic analyses of ALS patient cohorts, as well as samples derived from individual patients. This approach has allowed us to identify novel therapeutic targets at the cohort and individual patient level. Today I have prepared case studies highlighting some of the paths we have taken to identify general and personalized therapeutic candidates for ALS patients.